Please assess the completion status of the following clinical trial:

Trial Title: SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration.~* The patient has a diagnosis of American Joint Committee on Cancer (AJCC) 8th Edition stage IV NSCLC.~* The patient receives 3rd generation EGFR-TKI in the first line setting.~* The patient is ≥18 years of age and ≤75 years of age at the time of screening.~* The patient's Karnofsky performance score (KPS) is ≥70 at study entry.~* The patient has adequate baseline tumor assessment before initiation of 3rd generation EGFR-TKI.~* The patient has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.~* The patient presents with a residual oligometastatic state after 3rd generation EGFR-TKI therapy that would be amenable to consolidative SRT in the opinion of the investigator.~* The patient has signed informed consent.~* EGFR Exon19 deletion or Exon21 L858R mutation~Exclusion Criteria:~* History of another malignancy or concurrent malignancy. Patients with cervical carcinoma in situ or adequately treated basal cell carcinoma who have been disease free for \> 5 years are eligible.~* The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding.~* Patients with uncontrolled epilepsy, mental disorders, drug abuse, or social condition that may affect compliance or ability to sign a written informed consent in the opinion of the investigator.~* Patients with residual metastatic disease after 3rd generation EGFR-TKI therapy that is deemed not amenable to consolidative SRT.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3rd generation EGFR-TKI+ SRT (Type: EXPERIMENTAL): Patients were treated with the intent to ablate all residual disease with consolidative SRT. EGFR-TKI treatment was continued during and after consolidative SRT until disease progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).